Compugen shares rise on Pfizer pact

Shares of Compugen spiked in premarket trading when the biotech announced that it had struck a deal to collaborate with Pfizer on three new drug candidates. But investors were reacting largely on faith. Neither company outlined how much money was involved or what the targets are. Compugen release | Report

Suggested Articles

Half of patients in an early trial of Allogene's off-the-shelf CAR-T cells for lymphoma who received a higher dose of its antibody ALLO-647 responded.

Takeda is tossing out a Shire pipeline med after it couldn't find a buyer.

Ipsen's new hire arrives at a company reeling from a torrent six months that have crushed hopes for its $1 billion bet on a rare disease drug.